PRLD · Prelude Therapeutics Inc · Webcasts, Transcripts & Audio
$3.23
-0.03 (-0.77%)
At close · Nov 20
Return incl. dividend (before tax)
Play latest call
Q3 2025 earnings call transcript
Market Cap
$258.63M
Shares
80.07M
Volume · Nov 20
300.1K
Avg daily vol (3M)
434.45K
You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
Prelude Therapeutics Inc Webcasts
Earnings calls, investor updates, investor days and conferences for Prelude Therapeutics Inc (PRLD), with available transcripts, audio replays and slides. Earnings calls also include available highlights, earnings releases and periodic filings.
Pull transcripts and briefs through the earnings call transcript API or MCP →
Add these events to your calendar (.ics)
Conference
Investor event
2026-12-02
Prelude Therapeutics Inc (PRLD) December 2, 2026 Conference
Scheduled
No reported result — non-financial event
Audio
Transcript
Slides
Earnings call
FY26 · Q3
2026-11-16
Prelude Therapeutics Inc (PRLD) Q3 2026 Earnings Call
Revenue
$5.65M
▼ 13.1% YoY Diluted EPS
$-0.12
Rev · 7q
Audio
Transcript
Slides
8-K10-Q
Conference
Investor event
2026-10-20
Prelude Therapeutics Inc (PRLD) October 20, 2026 Conference Transcript
No reported result — non-financial event
Audio
Transcript
Slides
Conference
Investor event
2026-09-16
Prelude Therapeutics Inc (PRLD) September 16, 2026 Conference Transcript
No reported result — non-financial event
Audio
Transcript
Slides
Conference
Investor event
2026-06-10
Prelude Therapeutics Inc (PRLD) June 10, 2026 Conference Transcript
No reported result — non-financial event
Audio
Transcript
Slides
Conference
Investor event
2026-06-03
Prelude Therapeutics Inc (PRLD) June 3, 2026 Conference Transcript
No reported result — non-financial event
Audio
Transcript
Slides
Earnings call
FY25 · Q4
2026-03-10
Prelude Therapeutics Inc (PRLD) Q4 2025 Earnings Call
Revenue
$5.64M*
Rev · 4q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY25 · Q3
2025-11-12
Prelude Therapeutics Inc (PRLD) Q3 2025 Earnings Call Transcript
Positive tone
CAP-6A selective degrader program
Insight option agreement / business development
JAK2V617F selective inhibitor program
Revenue
$6.50M
▲ 116.7% YoY Diluted EPS
$-0.26
Rev · 4q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q1
2025-05-06
Prelude Therapeutics Inc (PRLD) Q1 2025 Earnings Call
Revenue
$0
Diluted EPS
$-0.42
Rev · 2q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q4
2025-03-10
Prelude Therapeutics Inc (PRLD) Q4 2024 Earnings Call
Results not yet reported
Audio
Transcript
Slides
8-K10-K
Earnings call
FY24 · Q3
2024-12-02
Prelude Therapeutics Inc (PRLD) Q3 2024 Earnings Call
Revenue
$3.00M
Diluted EPS
$-0.43
Audio
Transcript
Slides
8-K10-Q
Showing 1–11 of 11 webcasts
Key facts
CIK
1678660
CUSIP
74065P101
13F (30d)
104 filings
90 filers
Visit website
Investor relations